Skip to content
IV Infusion Allopathic

Beovu 6 mg/0.05 ml iv infusion

Generic: Brolucizumab

Company: Novartis (Bangladesh) Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength6 mg/0.05 ml
PackNot listed yet

Reviewed by: not listed yet. Source: not listed yet.

Last updated April 17, 2025.

Compare

Same generic, same strength

Sorted by price per iv infusion. Ask your pharmacist before you switch brands.

Brolucizumab 6 mg/0.05 ml iv infusions

Prices as listed on BestinMeds.

No price is listed for this strength yet.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Brolucizumab guide

Indications

Brolucizumab is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Diabetic Macular Edema (DME)

Dosage and administration

Neovascular (Wet) Age-Related Macular Degeneration (AMD): The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks. Diabetic Macular Edema (DME): The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) every six weeks (approximately every 39-45 days) for the first five doses, followed by one dose of 6 mg (0.05 mL of 120 mg/mL solution) every 8-12 weeks. Pediatric Use: The safety and efficacy of BEOVU in pediatric patients has not been established.

Side effects

The most common adverse reactions reported in patients receiving Brolucizumab are vision blurred, cataract, conjunctival hemorrhage, eye pain, and vitreous floaters.

Precautions and warnings

Endophthalmitis and retinal detachment may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay. Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported following BEOVU injections. Patients should be instructed to report any change in vision without delay. Increases in intraocular pressure (IOP) have been seen within 30 minutes of an intravitreal injection. There is a potential risk of arterial thromboembolic events (ATE) following intravitreal use of VEGF inhibitors

Pregnancy and lactation

There are no adequate and well-controlled studies of BEOVU administration in pregnant women. In an animal reproduction study, intravitreal administration of brolucizumab to pregnant monkeys once every 4 weeks in one eye from organogenesis to birth caused fetal loss and a structural abnormality (bilateral absent metatarsal) in offspring at 10-fold the maximum recommended human dose (MRHD) on a mg/kg basis. There is no information regarding the presence of brolucizumab in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production/excretion. Because many drugs are transferred in human milk and because of the potential for absorption and adverse reactions in the breastfed child, breastfeeding is not recommended during treatment and for at least one month after the last dose when stopping treatment with Brolucizumab.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250